Serina Therapeutics FY24 EPS $(1.51) Down From $0.73 YoY, Total Revenues $56K Down From $3.15M YoY
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Serina Therapeutics | 10-K: Annual report
Serina Therapeutics Unveils Breakthrough in POZ-Lipid Technology
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Serina Therapeutics Analyst Ratings
JonesTrading Initiates Serina Therapeutics(SER.US) With Buy Rating, Announces Target Price $11
Serina Therapeutics Initiated With a Buy at JonesResearch
Serina Therapeutics Appoints Dr. Jay Venkatesan to Its Board of Directors
Express News | Serina Therapeutics Appoints DR. Jay Venkatesan to Its Board of Directors
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics
Serina Therapeutics's Shares Up Following $5M of Equity Financing
Serina Therapeutics Secures $5 Million for SER-252 Trials
Express News | Serina Therapeutics Inc - Funding to Advance Ser-252 Into Phase 1 Trial in H2 2025
Express News | Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics
Express News | Serina Therapeutics Inc - Transaction Eliminates $11.2 Million in Debt
Serina Therapeutics Announces Sale of UniverXome Subsidiary
Serina Therapeutics Appoints Karen J. Wilson to Board of Directors